S&P 500   4,634.83 (+1.49%)
DOW   34,895.35 (+1.19%)
QQQ   398.13 (+1.09%)
AAPL   167.91 (+1.58%)
MSFT   335.01 (+1.34%)
FB   325.96 (+0.46%)
GOOGL   2,908.03 (+2.47%)
AMZN   3,535.43 (+0.81%)
TSLA   1,153.93 (+0.80%)
NVDA   328.70 (+0.59%)
BABA   127.39 (-0.11%)
NIO   39.98 (+2.17%)
CGC   10.78 (+0.65%)
AMD   157.56 (-0.51%)
GE   96.25 (+1.33%)
MU   88.28 (+5.10%)
T   23.03 (+0.88%)
F   20.25 (+5.52%)
DIS   147.55 (+1.83%)
ACB   6.44 (+0.31%)
PFE   53.59 (-0.26%)
AMC   34.17 (+0.68%)
BA   199.33 (+0.75%)
S&P 500   4,634.83 (+1.49%)
DOW   34,895.35 (+1.19%)
QQQ   398.13 (+1.09%)
AAPL   167.91 (+1.58%)
MSFT   335.01 (+1.34%)
FB   325.96 (+0.46%)
GOOGL   2,908.03 (+2.47%)
AMZN   3,535.43 (+0.81%)
TSLA   1,153.93 (+0.80%)
NVDA   328.70 (+0.59%)
BABA   127.39 (-0.11%)
NIO   39.98 (+2.17%)
CGC   10.78 (+0.65%)
AMD   157.56 (-0.51%)
GE   96.25 (+1.33%)
MU   88.28 (+5.10%)
T   23.03 (+0.88%)
F   20.25 (+5.52%)
DIS   147.55 (+1.83%)
ACB   6.44 (+0.31%)
PFE   53.59 (-0.26%)
AMC   34.17 (+0.68%)
BA   199.33 (+0.75%)
S&P 500   4,634.83 (+1.49%)
DOW   34,895.35 (+1.19%)
QQQ   398.13 (+1.09%)
AAPL   167.91 (+1.58%)
MSFT   335.01 (+1.34%)
FB   325.96 (+0.46%)
GOOGL   2,908.03 (+2.47%)
AMZN   3,535.43 (+0.81%)
TSLA   1,153.93 (+0.80%)
NVDA   328.70 (+0.59%)
BABA   127.39 (-0.11%)
NIO   39.98 (+2.17%)
CGC   10.78 (+0.65%)
AMD   157.56 (-0.51%)
GE   96.25 (+1.33%)
MU   88.28 (+5.10%)
T   23.03 (+0.88%)
F   20.25 (+5.52%)
DIS   147.55 (+1.83%)
ACB   6.44 (+0.31%)
PFE   53.59 (-0.26%)
AMC   34.17 (+0.68%)
BA   199.33 (+0.75%)
S&P 500   4,634.83 (+1.49%)
DOW   34,895.35 (+1.19%)
QQQ   398.13 (+1.09%)
AAPL   167.91 (+1.58%)
MSFT   335.01 (+1.34%)
FB   325.96 (+0.46%)
GOOGL   2,908.03 (+2.47%)
AMZN   3,535.43 (+0.81%)
TSLA   1,153.93 (+0.80%)
NVDA   328.70 (+0.59%)
BABA   127.39 (-0.11%)
NIO   39.98 (+2.17%)
CGC   10.78 (+0.65%)
AMD   157.56 (-0.51%)
GE   96.25 (+1.33%)
MU   88.28 (+5.10%)
T   23.03 (+0.88%)
F   20.25 (+5.52%)
DIS   147.55 (+1.83%)
ACB   6.44 (+0.31%)
PFE   53.59 (-0.26%)
AMC   34.17 (+0.68%)
BA   199.33 (+0.75%)
NASDAQ:PCRX

Pacira BioSciences Stock Forecast, Price & News

$54.15
+1.53 (+2.91%)
(As of 12/1/2021 10:38 AM ET)
Add
Compare
Today's Range
$53.13
$54.59
50-Day Range
$47.97
$58.96
52-Week Range
$45.05
$80.00
Volume
2,313 shs
Average Volume
452,776 shs
Market Capitalization
$2.41 billion
P/E Ratio
39.82
Dividend Yield
N/A
Beta
0.97
30 days | 90 days | 365 days | Advanced Chart
Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.


Pacira BioSciences logo

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Headlines

Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 4.8%
November 30, 2021 |  americanbankingnews.com
Expert Ratings For Pacira BioSciences
November 5, 2021 |  markets.businessinsider.com
Can Pacira Biosciences Go Up the Slope?
November 4, 2021 |  nasdaq.com
Pacira (PCRX) Beats Q3 Earnings Estimates
November 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
624
Year Founded
N/A

Sales & Book Value

Annual Sales
$429.65 million
Cash Flow
$2.13 per share
Book Value
$16.13 per share

Profitability

Net Income
$145.52 million
Pretax Margin
14.67%

Debt

Price-To-Earnings

Miscellaneous

Free Float
42,228,000
Market Cap
$2.41 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.21 out of 5 stars

Medical Sector

368th out of 1,392 stocks

Pharmaceutical Preparations Industry

165th out of 669 stocks

Analyst Opinion: 4.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -












Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view top-rated stocks.

How has Pacira BioSciences' stock been impacted by COVID-19 (Coronavirus)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PCRX stock has increased by 53.9% and is now trading at $54.15.
View which stocks have been most impacted by COVID-19
.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Pacira BioSciences
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.07. The company had revenue of $127.70 million for the quarter, compared to the consensus estimate of $129.69 million. Pacira BioSciences had a net margin of 12.01% and a trailing twelve-month return on equity of 14.39%. The company's quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the business earned $0.43 EPS.
View Pacira BioSciences' earnings history
.

What price target have analysts set for PCRX?

11 brokers have issued 12-month target prices for Pacira BioSciences' shares. Their forecasts range from $57.00 to $93.00. On average, they anticipate Pacira BioSciences' stock price to reach $79.55 in the next year. This suggests a possible upside of 46.9% from the stock's current price.
View analysts' price targets for Pacira BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (8.27%), Spyglass Capital Management LLC (4.96%), Baillie Gifford & Co. (4.70%), Renaissance Technologies LLC (4.42%), Paulson & CO. Inc. (2.83%) and Stephens Investment Management Group LLC (2.19%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, David M Stack, Dennis Mcloughlin, Donald C Manning, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which major investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Renaissance Technologies LLC, Millennium Management LLC, Schroder Investment Management Group, Dimensional Fund Advisors LP, Assenagon Asset Management S.A., and Peregrine Capital Management LLC. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, David M Stack, Donald C Manning, Kristen Marie Williams, Lauren Bullaro Riker, Max Reinhardt, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which major investors are buying Pacira BioSciences stock?

PCRX stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Spyglass Capital Management LLC, Jabodon PT Co., Gagnon Securities LLC, Tributary Capital Management LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp Et Al, and Voloridge Investment Management LLC.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $54.15.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.41 billion and generates $429.65 million in revenue each year. The company earns $145.52 million in net income (profit) each year or $1.36 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 624 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

Where are Pacira BioSciences' headquarters?

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at (813) 553-6680, via email at [email protected], or via fax at 302-655-5049.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.